Efficacy and Safety of First-Line Carboplatin- versus Cisplatin-based Chemotherapy for Non-Small Cell Lung Cancer: A Meta-Analysis

Lung cancer is the leading cause of cancer death worldwide, and non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers [1]. For advanced disease (stage IIIB-IV), first-line treatment options have evolved in recent years; however, the mainstay consists of platinum-based chemotherapy doublets [2,3].

Source: Lung Cancer - July 12, 2019 Category: Cancer & Oncology Authors: Frank Griesinger, Ellen E. Korol, Sheena Kayaniyil, Nebibe Varol, Timo Ebner, Sarah M. Goring Source Type: research